Bronte Capital Management Pty Ltd. Regeneron Pharmaceuticals, Inc. Transaction History
Bronte Capital Management Pty Ltd.
- $984 Million
- Q4 2024
A detailed history of Bronte Capital Management Pty Ltd. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Bronte Capital Management Pty Ltd. holds 152,783 shares of REGN stock, worth $105 Million. This represents 11.06% of its overall portfolio holdings.
Number of Shares
152,783
Previous 137,042
11.49%
Holding current value
$105 Million
Previous $144 Million
24.46%
% of portfolio
11.06%
Previous 12.83%
Shares
17 transactions
Others Institutions Holding REGN
# of Institutions
1,486Shares Held
83.7MCall Options Held
1.22MPut Options Held
1.5M-
Vanguard Group Inc Valley Forge, PA9.32MShares$6.43 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.83 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$5.17 Billion0.64% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.38 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$2.97 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $74B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...